KDM5A and KDM5B, which are commonly overexpressed in luminal breast cancer, modulate ER signaling, alter gene expression profiles, and promote endocrine therapy resistance [143,146,149,150,151,152,153]. Here, KDM5A is linked to breast carcinoma.